Publications and Presentations
Brooks KM , Momper JD, Pinilla M, Stek AM, Barr E, Weinberg A, Deville JG, Febo IL, Cielo M, George K, Denson K, Rungruengthanakit K, Shapiro DE, Smith E, Chakhtoura N, Rooney JF, Haubrich R, Espina R, Capparelli EV, Mirochnick M, Best BM, on behalf of the IMPAACT 1026s Team. Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV: Results from IMPAACT P1026s. AIDS. 2021 Mar 1;35(3):407-417. doi: 10.1097/QAD.0000000000002767. PMID: 33252495.
Brooks KM, Castillo-Mancilla JR, Morrow M, Mawhinney S, Blum J, Wyles D, Rowan S, Ibrahim M, Zheng JH, Johnson B, Gomez J, Cendali F, Haas H, Roon L, Bushman LR, Anderson PL, Kiser JJ. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother, 2020 Nov 1;75(11):3303-3310. doi: 10.1093/jac/dkaa299. PMID: 32766700.
Aizire J, Brooks KM, Mirochnick M, Flynn PM, Butler K, Kiser JJ, Siberry G, Fenton T, Cababasay M, Fowler MG, for the PROMISE Study Team. Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate during Pregnancy in the IMPAACT-PROMISE study: Description and Relationships with Adverse Pregnancy Outcomes. J Acquir Immune Defic Syndr, 2020 Feb 1;83(2):173-180. doi: 10.1097/QAI.0000000000002247. PMID: 31929405.
Brooks KM, George JM, Pau AK, Rupert A, Mehaffy C, De P, Dobos KM, Kellogg A, McLaughlin M, McManus ME, Alfaro RA, Hadigan C, Kovacs JA, Kumar P. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir with Once-Weekly Isoniazid and Rifapentine. Clin Infect Dis. 2018 Jul 2;67(2):193-201. doi: 10.1093/cid/ciy082. [Epub ahead of print]. PMID: 29415190.
Kim H*, Brooks KM*, Tang CC*, Wakim P, Blake M, Brooks S, Montealegre-Sanchez GA, de Jesus AA, Huang Y, Blake M, Tsai W, Gadina M, Prakash A, Janes JM, Zhang X, Macias B, Kumar P, Goldbach-Mansky R. Pharmacokinetics, Pharmacodynamics and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult Patients with CANDLE and SAVI. Clin Pharmacol Ther. 2018 Aug;104(2):364-373. doi: 10.1002/cpt.936. Epub 2017 Dec 8. PMID: 29134648. *authors contributed equally